FDA refuses approval of Pfizer's Lyrica for GAD
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter denying approval for Pfizer's Lyrica (pregabalin) as a monotherapy treatment for generalised anxiety disorder (GAD).